What are you looking for? Search Common searches: Intranet, Contact, Map, Professionals, Teaching units, Research groups, Fulltext search Tipus de contingut Professionals Projects Teaching Units Collaborating entities News Activities - Any - Search Activities Doctoral thesis Respiratory complications following SARS-CoV-2 infection Doctoral candidate: David Espejo CastellanosDirectors: Dr. María Jesús Cruz Carmona and Dr. Xavier Muñoz GallTutor: Dr. Jaume Ferrer Sancho News Vall d'Hebron shows the benefits on microbiota of a diet rich in vegetables, fruit, legumes and whole grains The study, involving a thousand participants from different regions of Spain, shows that diet influences the diversity and composition of the microbiota and, therefore, health. Activity aula Curs de Formació Bàsica d'Instructors en Simulació News FDA grants orphan drug designation to a gene therapy for ALS developed in collaboration with VHIR The treatment, licensed to Klotho Neurosciences, is based on a technology developed at the Universitat Autònoma de Barcelona (UAB) with the participation of VHIR. Activity aula Curs Avançat d'Instructors en Simulació Activity aula * XX Curs teòric - Pràctic de Ecocardiografia Bàsica i Avançada en Medicina de Urgència, Intensiva i Anestesia News Fundaluce supports research into a new therapeutic strategy for retinitis pigmentosa at Vall d’Hebron Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss. News RBDCOV final event highlights legacy and lessons learned The project, in which Vall d’Hebron participates, studied the Bimervax® vaccine in immunocompromised individuals and paediatric patients. News Strong presence of VHIR at the European Alliance of Associations for Rheumatology Congress 15 researchers from the Rheumatology, Systemic Diseases and the Physiology and Pathophysiology of the Digestive Tract groups gave around 25 presentations. News Formation Bio Licenses First-in-Class Anti-CD226 Autoimmune Program from IMIDomics Transaction expands Formation Bio's immunology pipeline with Phase 1 ready drug candidate. Pagination Previous page ‹‹ Page 258 Next page ››